EDGAR·FLOW

Keros Therapeutics, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 28/100
What the filing says
Keros Therapeutics' Board approved a $5 million share repurchase program following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals under the elritercept license agreement, triggered by dosing the first patient in the ELRiSE MF clinical trial. The repurchase authorization is discretionary with no obligation to execute and may be modified or suspended at any time.
Why this rating

Milestone payment is 4.4% of market cap; repurchase is 1.1%. Routine capital allocation tied to clinical progress, non-binding, and common for biotech. Modest positive signal from trial advancement.

View original filing on SEC.gov ↗ KROS · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.